F S&P 500
5,058.75 -8.25 (-0.16%) F Dow Jones
37,974.00 -19.00 (-0.05%) F Nasdaq
17,514.75 -56.50 (-0.32%) E-mini Russell 2000 Index Futur
1,986.60 +1.00 (+0.05%) Petróleo
80.63 -1.30 (-1.59%) Oro
2,306.60 +3.70 (+0.16%)
ESSA Pharma Inc. (EPIX)
ESSA Pharma Inc.
999 West Broadway
Suite 720
Vancouver, BC V5Z 1K5
Canada
778 331 0962
https://www.essapharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 50
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. David Ross Parkinson M.D. | President, CEO & Director | 814.15k | N/D | 1950 |
| Mr. David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA | Chief Financial Officer | 590.39k | N/D | 1957 |
| Mr. Peter A. Virsik M.B.A., M.S. | Executive VP & COO | 645.95k | N/D | 1971 |
| Dr. Alessandra Cesano M.D., Ph.D. | Chief Medical Officer & Executive VP | 623.93k | N/D | 1961 |
| Chandtip Chandhasin | Executive | N/D | N/D | N/D |
| Erica Osbourne | Executive | N/D | N/D | N/D |
| Erin Rudsinski | Executive | N/D | N/D | N/D |
| Loleta Harris | Executive | N/D | N/D | N/D |
| Neil Thapar | Executive | N/D | N/D | N/D |
| Nkengyal Barber | Executive | N/D | N/D | N/D |
Descripción
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de ESSA Pharma Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
